Abstract:Objective: Obesity alters sex hormone balance in males, resulting in low testosterone and altered metabolism of estrogen, independent risk factors for cardiometabolic dysfunction. The basis of these alterations and how they are impacted by factors that improve cardiometabolic outcomes in obesity are unknown. Methods: Control and obese mice ( db/db) with or without deletion of myostatin to induce hypermuscularity were used. Mice were analyzed for plasma sex hormones via mass-spectrometry with or without 10mg/kg/day fadrazole to inhibit aromatase. Quantitative PCR was used to measure aromatase along with cytochrome P450 enzymes involved in estrogen metabolism in the liver, skeletal muscle, and visceral adipose tissue. HEK293a cells were treated with myostatin in vitro and enzyme levels assessed. Results: Obesity decreased plasma testosterone 30% and increased estrogen 20% with no change in gonadal weight. Deletion of myostatin increased muscle mass >30% and resulted in a reduction in estrogen levels without a parallel increase in androgens in obese mice. Inhibition of aromatase restores estrogen levels indicating the excess estrogen in obesity is derived from testosterone conversion. Since estrogen was lowered without increasing testosterone and estrogen metabolism must be increased. Aromatase was increased in obesity but unaffected by changes in muscle mass. CYP1B1, an enzyme that converts estradiol to hydroxy estrogens, showed 2.5 fold expression in obese skeletal muscle, which is improved in the absence of myostatin, with no change in other P450s involved in estrogen metabolism. Moreover, changes in P450 enzymes in liver or fat were either absent or changed directionally opposite to observed hormone changes. In HEK cells, treatment with myostatin recapitulated changes in CYP1B1 expression seen in vitro, suggesting a direct link between the myokine and sex hormone metabolism by skeletal muscle. Conclusion: In summary, obesity causes a shift in sex hormone levels to estrogen production, which is improved by myostatin deletion, without restoration of androgens. A potential mechanism responsible could be altered estrogen catabolism, leading to decreased estrogen levels without the restoration of androgen levels. Together, these data suggest CYP1B1 drives the conversion of estrogen to hydroxestrogens, which are known pro-oxidant and pro-lipidemic influences that may contribute to cardiometabolic disease. Whether targeting CYP1B1 improves cardiometabolic function in obesity remains to be determined. D.W. Stepp and D.J. Fulton are supported by NIH 1R01HL147159 This is the full abstract presented at the American Physiology Summit 2023 meeting and is only available in HTML format. There are no additional versions or additional content available for this abstract. Physiology was not involved in the peer review process.

Osteocalcin has a muscle-protective effect during weight loss in men without metabolic syndrome: a multicenter, prospective, observational study

Reducing Undercarboxylated Osteocalcin With Vitamin K Supplementation Does Not Promote Lean Tissue Loss or Fat Gain Over 3 Years in Older Women and Men: A Randomized Controlled Trial

The relationship between changes in serum myostatin and adiponectin levels in patients with obesity undergoing a weight loss program

The Effects of E'Jiao on Body Composition, Bone Marrow Adiposity and Skeletal Redox Status in Ovariectomised Rats.

The influence of weight loss on serum osteoprotegerin concentration in obese perimenopausal women

Effects of weight loss rate on myostatin and follistatin dynamics in patients with obesity

Physical Activity Level and Dietary Intake Associated with Fat-Free Muscle Mass Changes During Intentional Weight Loss in Overweight and Obese Subjects

Intermittent injections of osteocalcin reverse autophagic dysfunction and endoplasmic reticulum stress resulting from diet-induced obesity in the vascular tissue via the NFκB-p65-dependent mechanism

Oleanolic acid alleviates obesity‐induced skeletal muscle atrophy via the PI3K/Akt signaling pathway

Osteocalcin protects islet identity in LDL receptor knockout mice on high fat diet

Metabolomic signatures for the longitudinal reduction of muscle strength over 10 years

Effect of Weight Loss on Skeletal Muscle Bioactive Lipids in People with Obesity and Type 2 Diabetes

Deletion of myostatin alters obesity-induced estrogen metabolism in skeletal muscle

Association of Initial Muscle Fitness with Weight Loss and Metabolically Healthy Status in Children and Adolescents with Obesity: A Retrospective Study

Osteoprotegerin--does it play a protective role in the pathogenesis of bone loss in obese perimenopausal women?

Oleocanthal Protects C2C12 Myotubes against the Pro-Catabolic and Anti-Myogenic Action of Stimuli Able to Induce Muscle Wasting In Vivo

Oligonol Alleviates Sarcopenia by Regulation of Signaling Pathways Involved in Protein Turnover and Mitochondrial Quality

Multi-Omics Exploration of Obesity Biomarkers in Sedentary and Weight Loss Cohorts

Osteocalcin, Glucose Metabolism, Lipid Profile and Chronic Low-Grade Inflammation in Middle-Aged and Elderly Chinese

Weight Loss Strategies and the Risk of Skeletal Muscle Mass Loss

The Effect of 8-Week Protein Supplementation with a Simple Exercise Program on Body Composition, Muscle Strength, and Amino Acid OMICS among Healthy Sedentary Indians: A Randomized, Double-Blind, Placebo-Controlled Trial